CN114887052A - 一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 - Google Patents
一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 Download PDFInfo
- Publication number
- CN114887052A CN114887052A CN202210532886.9A CN202210532886A CN114887052A CN 114887052 A CN114887052 A CN 114887052A CN 202210532886 A CN202210532886 A CN 202210532886A CN 114887052 A CN114887052 A CN 114887052A
- Authority
- CN
- China
- Prior art keywords
- parts
- multivitamin
- nutrient solution
- peptide
- cordyceps sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 40
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 22
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 21
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 21
- 241001076416 Dendrobium tosaense Species 0.000 claims abstract description 21
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 21
- 244000272459 Silybum marianum Species 0.000 claims abstract description 21
- 235000010841 Silybum marianum Nutrition 0.000 claims abstract description 21
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 21
- 150000001413 amino acids Chemical class 0.000 claims abstract description 21
- 239000010495 camellia oil Substances 0.000 claims abstract description 21
- 235000008397 ginger Nutrition 0.000 claims abstract description 21
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 20
- 241000283690 Bos taurus Species 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 20
- 108010035532 Collagen Proteins 0.000 claims abstract description 20
- 241000208688 Eucommia Species 0.000 claims abstract description 20
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 20
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 20
- 229920001436 collagen Polymers 0.000 claims abstract description 20
- 108010074605 gamma-Globulins Proteins 0.000 claims abstract description 20
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 20
- 230000009261 transgenic effect Effects 0.000 claims abstract description 20
- 239000000811 xylitol Substances 0.000 claims abstract description 20
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 20
- 229960002675 xylitol Drugs 0.000 claims abstract description 20
- 235000010447 xylitol Nutrition 0.000 claims abstract description 20
- 239000011787 zinc oxide Substances 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 17
- 244000251953 Agaricus brunnescens Species 0.000 claims abstract description 10
- 239000003674 animal food additive Substances 0.000 claims abstract description 4
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 5
- 235000015097 nutrients Nutrition 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 238000000855 fermentation Methods 0.000 claims description 17
- 230000004151 fermentation Effects 0.000 claims description 17
- 241000235395 Mucor Species 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000009098 adjuvant therapy Methods 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 abstract description 19
- 229940088594 vitamin Drugs 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 230000000857 drug effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 32
- 241000229143 Hippophae Species 0.000 description 16
- 241000234314 Zingiber Species 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 14
- 229960000939 metoprolol succinate Drugs 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000007939 sustained release tablet Substances 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000013265 extended release Methods 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- -1 polyethylene Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 240000000599 Lentinula edodes Species 0.000 description 3
- 235000001715 Lentinula edodes Nutrition 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000006806 disease prevention Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNOBZXNCABUBKK-UHFFFAOYSA-N 2,3,5-triphenyltetrazolium Chemical compound C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 LNOBZXNCABUBKK-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/06—Artificial hot-air or cold-air baths; Steam or gas baths or douches, e.g. sauna or Finnish baths
- A61H33/063—Heaters specifically designed therefor
- A61H33/065—Heaters specifically designed therefor with steam generators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/06—Artificial hot-air or cold-air baths; Steam or gas baths or douches, e.g. sauna or Finnish baths
- A61H33/066—Cabins therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及生物医药技术领域,更具体的说涉及一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用;所述多维素的原料包括:黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花、丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽。研究表明,本发明的多维素,能够显著提高心血管药物的药效,具有辅助治疗心血管疾病的作用。
Description
技术领域
本发明涉及生物医药技术领域,更具体的说涉及一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用。
技术背景
心血管病是指人体心脏及全身血管的一系列疾病。当前国内外对心血管疾病的防控给予了高度的重视,针对心血管疾病发生的危险因素积极采取措施进行防控。值得注意的是,虽然当前已经给予心血管疾病的防控高度的重视,但是绝大多数居民的自我保健意识和自我保健能力仍旧薄弱,如心血管疾病高危人群中很少有人摒弃以往存在的诸多不良的生活习惯,始终保持积极向上的乐观心态。再者,当前尚未完善的系统地针对高血压、糖尿病、肥胖、血脂异常、不良生活习惯等诸多可控的心血管疾病危险因素采取有效的管理和防控措施。也就是说,心血管疾病防控力度有待进一步加强,有必要针对诸多可控的心血管疾病危险因素,建立健全心血管疾病防控体系,采取更加有针对性有实效的防控措施,加大心血管疾病防治的宣传力度,增强居民的自我保健意识,提高其自我保健能力,以进一步降低心血管疾病的发病率和死亡率。
心血管疾病近年来的发病率持续上升,严重威胁着我国居民的健康。诸多因素会导致和诱发心血管疾病的发生,影响因素中有可控因素,也有不可控因素。针对诸多可控因素实施必要的防控和干预,将有助于心血管疾病发生率的降低,有助于心血管疾病死亡率的降低,有助于心血管疾病患者良好预后的获得。医药学发展至今,治疗心血管疾病的药物有若干种,包括化学药、生物药等等,而中药做为辅助治疗的一种手段,有着举重若轻的作用,因此,研究发展一种能够新的组合物,从而提高化药或生物药的疗效,降低其副作用,具有重要意义。
发明内容
基于上述原因,申请人经过若干次创造性的劳动,获得了一种可辅助治疗心血管疾病的多维素,所述多维素的原料药包括:黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花、丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽。研究表明,本发明的多维素,能够显著提高治疗心血管疾病药物的药效,具有辅助治疗治疗心虚管疾病的作用。
本发明通过下述技术方案实现的。
一种可辅助治疗心血管的多维素,所述多维素的原料包括:黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花、丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽。
所述多维素的原料包括:黄连叶4-6重量份、水飞蓟5-15重量份、生姜5-15重量份、冬虫夏草5-15重量份、铁皮石斛5-15重量份、红参5-15重量份、杜仲雄花5-15重量份、丙种球蛋白10-20重量份、非转基因大豆卵磷脂10-20重量份、山茶油20-40重量份、沙棘籽油10-20重量份、香菇肽4-6重量份、氨基酸4-6重量份、低聚异麦芽糖5-15重量份、木糖醇5-15重量份、纳米氧化锌0.4-0.6重量份、牛骨胶原蛋白肽4-6重量份。
所述的多维素的原料包括:黄连叶5重量份、水飞蓟10重量份、生姜10重量份、冬虫夏草10重量份、铁皮石斛10重量份、红参10重量份、杜仲雄花10重量份、丙种球蛋白15 重量份、非转基因大豆卵磷脂15重量份、山茶油30重量份、沙棘籽油15重量份、香菇肽5 重量份、氨基酸5重量份、低聚异麦芽糖10重量份、木糖醇10重量份、纳米氧化锌0.5重量份、牛骨胶原蛋白肽5重量份。
本发明所述的原料均够自沈耀(香河)科技有限公司;
本发明所述的氨基酸为包括甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、甲硫氨酸(蛋氨酸)、脯氨酸、色氨酸、丝氨酸、酪氨酸、半胱氨酸、苯丙氨酸、天门冬酰胺、谷氨酰胺、苏氨酸、天冬氨酸、谷氨酸、赖氨酸、精氨酸、组氨酸,均为相同重量。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的20-30倍,煎煮150-200分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.25%-0.65%,加入红糖量为混合营养液重量的5%-8%,发酵80-100天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的30%-50%,静置12-24小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
所述的多维素在制备辅助治疗心血管疾病药物中的应用。
本发明在使用多维素与使用治疗心血管疾病药物治疗时,可以使用小分子水蒸汽体疗舱:所述小分子水蒸汽体疗舱内安装旋磁、远红外线,贴上4块加磁的陨石,并在蒸汽锅内500 克太赫兹能量石。更进一步,小分子水蒸汽体疗舱中能够产生远红外线、太赫兹、旋磁波长可以穿透细胞组织,不停交叉,可以打通经络、促进血液循环,与小分子水互相作用,清洗细胞组织。
本发明从多种珍稀中药、植物和食物中提取的“多维素”,含有多种维生素、微量元素、丰富的蛋白质和矿物质,可以迅速均衡营养,补充能量,增强免疫力,依靠自身的免疫系统和自愈功能杀灭细菌和病毒,修复受损的细胞,促进细胞再生能力和新陈代谢。另一方面,采用小分子水蒸气体疗,把从蛋白质经过多次发酵萃取的纳米级活性溶毒酶(根据专利申请号2021102481928实施例1制备得到)添加在小分子水中,对患者进行水蒸气体疗,扩张毛细孔,把体内的自由基和杀死的细菌和病毒排出,纳米级活性溶毒酶进入体内细胞组织辅助免疫系统杀死细菌和病毒。通过食用多维素,补充营养,均衡营养,快速恢复自身的免疫功能。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
实施例1
多维素的原料配方:黄连叶50g、水飞蓟100g、生姜100g、冬虫夏草100g、铁皮石斛100g、红参100g、杜仲雄花100g、丙种球蛋白150g、非转基因大豆卵磷脂150g、山茶油300g、沙棘籽油150g、香菇肽50g、氨基酸50g、低聚异麦芽糖100g、木糖醇100g、纳米氧化锌5g、牛骨胶原蛋白肽50g。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的25倍,煎煮180分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.45%,加入红糖量为混合营养液重量的6.5%,发酵90天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的40%,静置18小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
实施例2
多维素的原料药配方:黄连叶40g、水飞蓟50g、生姜50g、冬虫夏草50g、铁皮石斛50g、红参50g、杜仲雄花50g、丙种球蛋白100g、非转基因大豆卵磷脂100g、山茶油200g、沙棘籽油100g、香菇肽40g、氨基酸40g、低聚异麦芽糖50g、木糖醇50g、纳米氧化锌4g、牛骨胶原蛋白肽40g。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的30倍,煎煮200分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.65%,加入红糖量为混合营养液重量的8%,发酵100天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的50%,静置24小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
实施例3
多维素的原料药配方:黄连叶60g、水飞蓟150g、生姜150g、冬虫夏草150g、铁皮石斛 150g、红参150g、杜仲雄花150g、丙种球蛋白200g、非转基因大豆卵磷脂200g、山茶油400g、沙棘籽油200g、香菇肽60g、氨基酸60g、低聚异麦芽糖150g、木糖醇150g、纳米氧化锌6g、牛骨胶原蛋白肽60g。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的20倍,煎煮150分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.25%,加入红糖量为混合营养液重量的5%,发酵80天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的30%,静置12小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
实施例4
多维素的原料药配方:黄连叶45g、水飞蓟65g、生姜65g、冬虫夏草65g、铁皮石斛75g、红参65g、杜仲雄花75g、丙种球蛋白130g、非转基因大豆卵磷脂125g、山茶油245g、沙棘籽油135g、香菇肽45g、氨基酸45g、低聚异麦芽糖55g、木糖醇65g、纳米氧化锌5g、牛骨胶原蛋白肽45g。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的28倍,煎煮190分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.60%,加入红糖量为混合营养液重量的7.5%,发酵95天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的30%-50%,静置12-24小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
实施例5
多维素的原料药配方:黄连叶55g、水飞蓟140g、生姜140g、冬虫夏草140g、铁皮石斛 140g、红参145g、杜仲雄花140g、丙种球蛋白195g、非转基因大豆卵磷脂190g、山茶油385g、沙棘籽油190g、香菇肽55g、氨基酸55g、低聚异麦芽糖145g、木糖醇140g、纳米氧化锌5g、牛骨胶原蛋白肽55g。
所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的22倍,煎煮165钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.3%,加入红糖量为混合营养液重量的5.5%,发酵85天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的35%,静置15小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
对比例1
本对比例与实施例1的区别仅在于缺少了黄连叶、铁皮石斛,其他的原料药和制备方法均与实施例1相同。
对比例2
本对比例与实施例1的区别仅在于缺少了水飞蓟、生姜,其他的原料药和制备方法均与实施例1相同。
对比例3
本对比例与实施例1的区别仅在于缺少了山茶油、沙棘籽油、香菇肽,其他的原料药和制备方法均与实施例1相同。
试验例1
对对小鼠心肌缺血再灌注损伤的影响
试验动物:雄性C57BL/6J小鼠,3-4个月。
试验药物:
试验1组:琥珀酸美托洛尔缓释片组。
试验2组:琥珀酸美托洛尔缓释片+实施例1组。
试验3组:琥珀酸美托洛尔缓释片+实施例2组。
试验4组:琥珀酸美托洛尔缓释片+实施例3组。
试验5组:琥珀酸美托洛尔缓释片+实施例4组。
试验6组:琥珀酸美托洛尔缓释片+实施例5组。
试验7组:琥珀酸美托洛尔缓释片+对比例1组。
试验8组:琥珀酸美托洛尔缓释片+对比例2组。
试验9组:琥珀酸美托洛尔缓释片+对比例3组。
试验方法:取C57BL/6J小鼠,随机分组:(1)缺血再罐组:每日给予1ml0.9%生理盐水,空腹灌胃1次,连续3d后,小鼠以4%戊巴比妥钠腹腔注射麻醉,给药剂量40mg/kg,待小鼠麻醉后,胸前区去毛,仰卧固定于鼠台,行气管插管后连接小动物呼吸机维持通气。胸前区消毒,于心尖搏动处纵行逐层分离皮肤、肌层,挣开4-5肋骨,暴露心脏,剥离心包膜,并以8-0丝线在距离左心耳下缘2毫米左右处穿过心肌表层,在肺动脉圆锥旁出针,在结扎LAD时连同一50号聚乙烯管一同结扎,进行缺血实验。给予4mm水正压通气,挤出胸腔内空气后关闭胸腔。在缺血45分钟后,重新打开胸腔,移除50号聚乙烯管,恢复再灌注3 小时。(2)各试验组:试验1组:每天灌胃给予琥珀酸美托洛尔,给药量为7.5mg/kg,连续3天后,小鼠以4%戊巴比妥钠腹腔注射麻醉,给药剂量40mg/kg,待小鼠麻醉后,胸前区去毛,仰卧固定于鼠台,行气管插管后连接小动物呼吸机维持通气。胸前区消毒,于心尖搏动处纵行逐层分离皮肤、肌层,挣开4-5肋骨,暴露心脏,剥离心包膜,并以8-0丝线在距离左心耳下缘2毫米左右处穿过心肌表层,在肺动脉圆锥旁出针,在结扎LAD时连同一50号聚乙烯管一同结扎,进行缺血实验。给予4mm水正压通气,挤出胸腔内空气后关闭胸腔。在缺血45分钟后,重新打开胸腔,移除50号聚乙烯管,恢复再灌注3小时。试验2组-试验9 组,每天灌胃给予琥珀酸美托洛尔,给药量为7.5mg/kg,同时灌胃给予各实施例或对比例的产品,给药量为1.35g/kg,连续3天后,同试验1组麻醉小鼠等操作。心肌梗死面积的测定:缺血45分钟后,再灌注3小时后打开胸腔,再次结扎LAD,自主动脉根部逆行注入1%浓度伊文思蓝染液1ml使相应冠状动脉所灌注的心肌着色(而结扎血管远端心肌即缺血危险区不着色)。处死小鼠,取出心脏,分离出左心室,从心尖起横向切成均匀等厚的4片薄片,置于 1%的氯化三苯基四氮哇磷酸缓冲液中,37℃常温孵育15分钟。采用高分辨率解剖显微镜对每片心肌组织进行拍照。使用图像分析系统对每块染色区域进行定量分析。正常区域(蓝色)、危险区域(红色)和梗死区域(白色)的大小用总体积的质量百分比表示,心肌梗死范围的大小以梗死区质量除以缺血危险区的质量表示。
试验结果:见表1。
表1对小鼠心肌缺血再灌注的影响(24h后)
注:与模型组比较***P<0.001,**P<0.01,*P<0.05;与试验7组比较#P<0.05。
试验结论:上述试验数据表明,本发明的多维素辅助琥珀酸美托洛尔对心肌的保护效果,而对比例1-3(即去掉某些原料)辅助效果消失,与琥珀酸美托洛尔的药效作用相近,充分说明本发明多维素具有很好的辅助治疗心血管疾病的作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (5)
1.一种辅助治疗心血管疾病的多维素,其特征在于,所述多维素的原料包括:黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花、丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽。
2.根据权利要求1所述的多维素,其特征在于,所述多维素的原料包括:黄连叶4-6重量份、水飞蓟5-15重量份、生姜5-15重量份、冬虫夏草5-15重量份、铁皮石斛5-15重量份、红参5-15重量份、杜仲雄花5-15重量份、丙种球蛋白10-20重量份、非转基因大豆卵磷脂10-20重量份、山茶油20-40重量份、沙棘籽油10-20重量份、香菇肽4-6重量份、氨基酸4-6重量份、低聚异麦芽糖5-15重量份、木糖醇5-15重量份、纳米氧化锌0.4-0.6重量份、牛骨胶原蛋白肽4-6重量份。
3.根据权利要求1所述的多维素,其特征在于,所述的多维素的原料包括:黄连叶5重量份、水飞蓟10重量份、生姜10重量份、冬虫夏草10重量份、铁皮石斛10重量份、红参10重量份、杜仲雄花10重量份、丙种球蛋白15重量份、非转基因大豆卵磷脂15重量份、山茶油30重量份、沙棘籽油15重量份、香菇肽5重量份、氨基酸5重量份、低聚异麦芽糖10重量份、木糖醇10重量份、纳米氧化锌0.5重量份、牛骨胶原蛋白肽5重量份。
4.根据权利要求1-3任一项所述的一种可辅助治疗心血管疾病的多维素,其特征在于,所述的多维素的制备方法为:
第一步:将黄连叶、水飞蓟、生姜、冬虫夏草、铁皮石斛、红参、杜仲雄花加水,加水量为冬虫夏草重量的20-30倍,煎煮150-200分钟,采用800目过滤网进行过滤,得出混合营养液,再将营养液置于发酵罐中,添加毛霉菌和红糖进行发酵,加入毛霉菌量为混合营养液重量的0.25%-0.65%,加入红糖量为混合营养液重量的5%-8%,发酵80-100天后取出,加入无水乙醇,加入乙醇量为混合营养液重量的30%-50%,静置12-24小时,过滤,得到过滤液备用;
第二步:将第一步的得到备用过滤液,与丙种球蛋白、非转基因大豆卵磷脂、山茶油、沙棘籽油、香菇肽、氨基酸、低聚异麦芽糖、木糖醇、纳米氧化锌、牛骨胶原蛋白肽混合搅拌均匀,得到所述多维素。
5.根据权利要求1-4任一项所述的多维素在制备辅助治疗心血管疾病药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210532886.9A CN114887052A (zh) | 2022-05-11 | 2022-05-11 | 一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210532886.9A CN114887052A (zh) | 2022-05-11 | 2022-05-11 | 一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114887052A true CN114887052A (zh) | 2022-08-12 |
Family
ID=82723902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210532886.9A Pending CN114887052A (zh) | 2022-05-11 | 2022-05-11 | 一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114887052A (zh) |
-
2022
- 2022-05-11 CN CN202210532886.9A patent/CN114887052A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102697035A (zh) | 虫草褔寿丹 | |
CN109757732A (zh) | 一种口服流质多肽粉及其制备方法 | |
CN101020715B (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
CN103405577B (zh) | 一种增强免疫力、缓解疲劳的药用组合物 | |
CN110420315A (zh) | 枸杞糖肽在制备治疗三高药物中的应用 | |
CN102161962A (zh) | 鹿茸血酒及其生产工艺 | |
CN104306554B (zh) | 一种治疗胃溃疡的食品、保健品或药物组合物 | |
WO2022165700A1 (zh) | 一种多肽营养粉及其制备方法 | |
CN112617196A (zh) | 一种抗缺氧、抗疲劳的食品、保健品或药物组合物及其制备方法和用途 | |
US20110318333A1 (en) | Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease | |
CN114887052A (zh) | 一种辅助治疗心血管疾病的蒸汽设备多维素及其制备方法和应用 | |
CN102631492B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN106214844A (zh) | 一种具有减肥和免疫调节作用的组合物及其制备方法 | |
CN105995971A (zh) | 一种促进糖尿病康复的营养流食及其制备方法 | |
CN102125576A (zh) | 甘草苷在制备防治心脑血管疾病药物中的应用 | |
CN114887040A (zh) | 一种辅助治疗糖尿病的蒸汽设备多维素及其制备方法和应用 | |
CN102631487B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN115518150A (zh) | 一种辅助调节血压的蒸汽设备多维素及其制备方法和应用 | |
CN102631506B (zh) | 提高免疫力、抗疲劳的中药组合物 | |
CN102631486B (zh) | 一种保健组合物 | |
CN107596013A (zh) | 一种玛咖的提取方法及其制备的男性保健品 | |
CN108236714B (zh) | 缓解体力疲劳和辅助降血脂的组合物及其软胶囊 | |
CN108452047B (zh) | 延缓衰老抑制肿瘤细胞生长改善心脑血管微循环的组合物 | |
CN105560441B (zh) | 一种温肾健髓、益气养阴、生血止血的中药组合物及其制备方法 | |
CN106173820A (zh) | 一种防治高血压心脏病的营养配方纳米颗粒及制备加工方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |